297 related articles for article (PubMed ID: 30109944)
1. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
[TBL] [Abstract][Full Text] [Related]
2. Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen.
Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2016 Oct; 14(8):453-477. PubMed ID: 27606620
[TBL] [Abstract][Full Text] [Related]
3. High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.
Hua Y; Shun TY; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2014 Sep; 12(7):395-418. PubMed ID: 25181412
[TBL] [Abstract][Full Text] [Related]
4. High Content Positional Biosensor Assay to Screen for Compounds that Prevent or Disrupt Androgen Receptor and Transcription Intermediary Factor 2 Protein-Protein Interactions.
Hua Y; Camarco DP; Strock CJ; Johnston PA
Methods Mol Biol; 2018; 1683():211-227. PubMed ID: 29082495
[TBL] [Abstract][Full Text] [Related]
5. Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor.
Fancher AT; Hua Y; Strock CJ; Johnston PA
Assay Drug Dev Technol; 2019; 17(8):364-386. PubMed ID: 31502857
[TBL] [Abstract][Full Text] [Related]
6. Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer.
Fancher AT; Hua Y; Close DA; Xu W; McDermott LA; Strock CJ; Santiago U; Camacho CJ; Johnston PA
SLAS Discov; 2023 Aug; ():. PubMed ID: 37549772
[TBL] [Abstract][Full Text] [Related]
7. Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.
Johnston PA; Nguyen MM; Dar JA; Ai J; Wang Y; Masoodi KZ; Shun T; Shinde S; Camarco DP; Hua Y; Huryn DM; Wilson GM; Lazo JS; Nelson JB; Wipf P; Wang Z
Assay Drug Dev Technol; 2016 May; 14(4):226-39. PubMed ID: 27187604
[TBL] [Abstract][Full Text] [Related]
8. Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.
Dudgeon DD; Shinde S; Hua Y; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
J Biomol Screen; 2010 Aug; 15(7):766-82. PubMed ID: 20639499
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
10. 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
Saito Y; Mizokami A; Tsurimoto H; Izumi K; Goto M; Nakagawa-Goto K
Eur J Med Chem; 2018 Sep; 157():1143-1152. PubMed ID: 30189396
[TBL] [Abstract][Full Text] [Related]
11. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
[TBL] [Abstract][Full Text] [Related]
12. Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.
Dudgeon DD; Shinde SN; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
Assay Drug Dev Technol; 2010 Aug; 8(4):437-58. PubMed ID: 20662736
[TBL] [Abstract][Full Text] [Related]
13. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
14. Prolonged androgen receptor loading onto chromatin and the efficient recruitment of p160 coactivators contribute to androgen-independent growth of prostate cancer cells.
Shi XB; Xue L; Zou JX; Gandour-Edwards R; Chen H; deVere White RW
Prostate; 2008 Dec; 68(16):1816-26. PubMed ID: 18780293
[TBL] [Abstract][Full Text] [Related]
15. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
18. The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade.
Rosette C; Agan FJ; Rosette N; Mazzetti A; Moro L; Gerloni M
Mol Cancer Ther; 2020 Nov; 19(11):2256-2266. PubMed ID: 32847976
[TBL] [Abstract][Full Text] [Related]
19. Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.
Siddique HR; Mishra SK; Karnes RJ; Saleem M
Clin Cancer Res; 2011 Aug; 17(16):5379-91. PubMed ID: 21712449
[TBL] [Abstract][Full Text] [Related]
20. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain.
Hua Y; Azeem W; Shen Y; Zhang S; Olsen JR; Øyan AM; Ke X; Zhang W; Kalland KH
Pharmacol Res Perspect; 2018 Dec; 6(6):e00437. PubMed ID: 30410767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
